{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-001917","form_type":"8-K","ticker":"BRGX","cik":"0001593184","company_name":"BIOREGENX, INC.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.133847+00:00","generated_at":"2026-06-04T04:40:02.188957+00:00","sec_items":["2.01","3.02","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"BioRegenx completes reverse merger with Findit; new board, name change effective March 8, 2024","bullets":["BioRegenx merged into Findit (OTC Pink: FDIT); surviving entity renamed BioRegenx, Inc.","Former BioRegenx holders received 851,977,296 common + 3,800 Series A preferred shares, representing 90% voting control.","Prior shareholders retired 98.47% voting control preferred shares and 172,197,602 common shares.","New officers appointed: William Resides CEO/interim CFO; board expanded to 7 directors.","Authorized common stock increased to 1.5B shares; press release notes GlycoCheck device ($22k-$32k system) and DocSun 40% revenue share, $10/vehicle license fee."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-001917","json":"https://secwatch.observer/filing/0001683168-24-001917.json","markdown":"https://secwatch.observer/filing/0001683168-24-001917.md","text":"https://secwatch.observer/filing/0001683168-24-001917.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/bioregenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:40:02.188957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"055fa374d1","claim":"Sherri Adams was appointed as director at BIOREGENX, INC..","evidence_excerpt":"the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"287d82004b","claim":"Gary Hennerberg was appointed as Secretary at BIOREGENX, INC..","evidence_excerpt":"the following officers were appointed: William Resides – Chief Executive Officer, Interim Financial Officer Robert Doran – Executive Vice President Sherri Adams – Chief Operating Officer Gary Hennerberg – Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Secretary"}],"fact_type":"executive_change"},{"claim_id":"44ba0c25f4","claim":"Jody Walker was appointed as director at BIOREGENX, INC..","evidence_excerpt":"the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"5ac2608590","claim":"Gary Hennerberg was appointed as director at BIOREGENX, INC..","evidence_excerpt":"the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"7a0cc6db5d","claim":"Robert Doran was appointed as director at BIOREGENX, INC..","evidence_excerpt":"the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"7b0b52efe1","claim":"Raymond Firth resigned as director at BIOREGENX, INC..","evidence_excerpt":"Effective March 8, 2024, Raymond Firth resigned as a director of the Registrant","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"88dfd0b2bc","claim":"William Resides was appointed as director at BIOREGENX, INC..","evidence_excerpt":"the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"90abe8cd71","claim":"Sherri Adams was appointed as Chief Operating Officer at BIOREGENX, INC..","evidence_excerpt":"the following officers were appointed: William Resides – Chief Executive Officer, Interim Financial Officer Robert Doran – Executive Vice President Sherri Adams – Chief Operating Officer Gary Hennerberg – Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"b4b25463d4","claim":"Robert Doran was appointed as Executive Vice President at BIOREGENX, INC..","evidence_excerpt":"the following officers were appointed: William Resides – Chief Executive Officer, Interim Financial Officer Robert Doran – Executive Vice President Sherri Adams – Chief Operating Officer Gary Hennerberg – Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President"}],"fact_type":"executive_change"},{"claim_id":"c49a808d0f","claim":"Suzanne Bird was appointed as director at BIOREGENX, INC..","evidence_excerpt":"the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"c8604397d2","claim":"Thomas Powers resigned as other_named_officer at BIOREGENX, INC..","evidence_excerpt":"Effective March 8, 2024, Raymond Firth and Thomas Powers resigned as officers of the Registrant","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"cce530aea9","claim":"Gary Kiss was appointed as director at BIOREGENX, INC..","evidence_excerpt":"the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides, Robert Doran, Sherri Adams, Gary Hennerberg, Suzanne Bird, Jody Walker, Gary Kiss","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"cde74aab56","claim":"Raymond Firth resigned as other_named_officer at BIOREGENX, INC..","evidence_excerpt":"Effective March 8, 2024, Raymond Firth and Thomas Powers resigned as officers of the Registrant","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"f1f2e0d73f","claim":"William Resides was appointed as Chief Executive Officer, Interim Financial Officer at BIOREGENX, INC..","evidence_excerpt":"the following officers were appointed: William Resides – Chief Executive Officer, Interim Financial Officer Robert Doran – Executive Vice President Sherri Adams – Chief Operating Officer Gary Hennerberg – Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer, Interim Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"051db14fcdc2022fdcfe6acd33f176c3662e1879","claim":"BIOREGENX, INC.: Company name changed to BioRegenx, Inc (effective 2024-03-08).","evidence_excerpt":"Additionally, the name of the Registrant was changed to BioRegenx, Inc.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-03-08"}],"fact_type":"governance_change"},{"claim_id":"3c135e37eafa9f1adedc09ad172fa45e69c2cb1c","claim":"BIOREGENX, INC.: Filed Certificate of Designation to cure 2013 creation of Series A preferred shares (effective 2024-03-14).","evidence_excerpt":"Effective March 14, 2024, the Registrant filed a Certificate of Designation (and subsequently, a Certificate of Correction) curing the 2013 creation of the Series A preferred shares and ratifying the issuances of 5,000,000 Series A preferred shares in 2013","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-03-14"}],"fact_type":"governance_change"},{"claim_id":"ffff9650d9475bcd3f90142f12b9179879ccf341","claim":"BIOREGENX, INC.: Increased authorized common stock to 1.5 billion shares (effective 2024-03-08).","evidence_excerpt":"Effective March 8, 2024, the Registrant filed an Amendment to the Articles of Incorporation which increased the authorized common stock to One Billion Five Hundred Thousand (1,500,000,000) common shares.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-03-08"}],"fact_type":"governance_change"},{"claim_id":"8a6f76cf58a1ac7d10024f9e901da904364c35cf","claim":"BIOREGENX, INC. underwent a change of control involving BioRegenx, Inc. (closed 2024-03-08).","evidence_excerpt":"The Registrant filed Articles of Merger effective March 8, 2024 with the state of Nevada. Pursuant to the Articles of Merger, BioRegenx, Inc, a Nevada corporation was merged into the Registrant with the Registrant being the surviving company.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"BioRegenx, Inc."},{"label":"Closing","value":"2024-03-08"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}